Results for "HMH Holding"

HMH Holding Inc. and SAB Biotherapeutics have both released their second-quarter financial results. These reports provide updates on their respective company performances for the recent quarter.

HMH Holding has priced its U.S. initial public offering at $20 per share and is preparing to list on the Nasdaq stock exchange.

HMH Holding, backed by Baker Hughes, is seeking a valuation of up to $948 million in its upcoming US initial public offering.